BIOVECTRA is a North American-based contract development and manufacturing organisation (CDMO) with over 50 years of experience in pharmaceutical and biotech manufacturing.
The company supports clinical-to-commercial scale production of regulated active pharmaceutical ingredients (APIs), biologics, plasmid DNA (pDNA), messenger RNA (mRNA), lipid nanoparticles (LNPs), small molecules and bioreagents.
Headquartered in Charlottetown, Prince Edward Island, Canada, with additional facilities in Atlantic Canada, BIOVECTRA emphasises flexibility, innovation, process optimisation and regulatory compliance in its service offering.
The company is equipped to handle complex therapeutic projects and high-potency APIs while ensuring scalable manufacturing solutions for its clients across phases.

Key products and services

• Contract development and manufacturing of biologics (microbial fermentation, recombinant proteins and biologic drug substances).
• Small-molecule API and intermediate development and manufacturing from early-phase through to commercial scale.
• Nucleic acid modalities including pDNA, mRNA and lipid nanoparticle (LNP) formulation and manufacturing.
• High-potency API (HPAPI) process development and manufacturing support.
• Project support services including process and analytical development, tech transfer, scale-up, commercial manufacturing and regulatory/compliance support.

With a longstanding track record and a wide range of modalities supported, BIOVECTRA positions itself as a partner for pharmaceutical and biotech clients seeking an end-to-end CDMO capable of transitioning programmes from development through to commercial supply. Its commitment to quality, process innovation, and operational scale means it is well-placed to support the evolving demands of modern therapeutics manufacturing.